Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure.

Govind Shantharam,Ali Amin,Jorge Pereira,Ohad Kott,Catrina Mueller-Leonhard,Anthony Mega,Dragan Golijanin,Boris Gershman

Current urology（2021）

引用 1|浏览2

暂无评分

摘要

In this first external validation study, intravesical docetaxel was associated with excellent response rates and intermediate-term RFS among patients with high-risk NMIBC after failed BCG therapy.

查看译文

关键词

Bacillus Calmette-Guérin,Docetaxel,Intravesical instillation,Nonmuscle invasive bladder cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要